Delving into the Latest Updates on ISA-201 with Synapse

Overview

Basic Info

Drug Type

Synthetic peptide vaccine, Therapeutic vaccine

Synonyms

Hespecta

+ [1]

Target

HPV E6

Mechanism

HPV E6 inhibitors(HPV E6 inhibitors)

Therapeutic Areas

NeoplasmsInfectious Diseases

Active Indication

Head and Neck NeoplasmsHuman Papillomavirus Infection

Inactive Indication

Human Papillomavirus-16 PositivePrecancerous ConditionsVisible Lesion

Originator Organization

ISA Pharmaceuticals BV

Active Organization

ISA Pharmaceuticals BV

Inactive Organization-

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

The H5N1 subtype highly pathogenic avian influenza virus (HPAIV) reveals high variability and threatens poultry production and public health. To prevent the spread of H5N1 HPAIV, we developed an H5N1 virus-like particle (VLP) vaccine based on the insect cell-baculovirus expression system. Single immunization of the H5N1 VLP vaccines induced high levels of HI antibody titres and provided effective protection against homologous virus challenge comparable to the commercial inactivated vaccine. Meanwhile, we assessed the relative efﬁcacy of different adjuvants by carrying out a head-to-head comparison of the adjuvants ISA 201 and ISA 71 and evaluated whether the two adjuvants could induce broadly protective immunity. The ISA 71 adjuvanted vaccine induced significantly higher levels of Th1 and Th2 immune responses and provided superior cross-protection against antigenically divergent H5N1 virus challenge than the ISA 201 adjuvanted vaccine. Importantly, increasing the vaccine dose could further enhance the cross-protective efficacy of H5N1 VLP vaccine and confer completely sterilizing protection against antigenically divergent H5N1 virus challenge, which was mediated by neutralizing antibodies. Our results suggest that the H5N1 VLP vaccine can provide broad-spectrum protection against divergent H5N1 influenza viruses as determined by adjuvant and vaccine dose.

01 Oct 2024·Vaccine

Superior protection against paratuberculosis by a heterologous prime-boost immunization in a murine model

Article

Author: Cuerda, María Ximena ; de la Paz Santangelo, María ; Gravisaco, María José ; Moyano, Roberto Damián ; Pinedo, María Fiorella Alvarado ; Delgado, Fernando Oscar ; Calamante, Gabriela ; Mundo, Silvia ; Del Medico Zajac, María Paula ; Romano, María Isabel ; Alonso, María Natalia ; Colombatti Olivieri, María Alejandra

Vaccination is the best strategy to control Paratuberculosis (PTB), which is a significant disease in cattle and sheep. Previously we showed the humoral and cellular immune response induced by a novel vaccine candidate against PTB based on the Argentinian Mycobacterium avium subspecies paratuberculosis (Map) 6611 strain. To improve 6611 immunogenicity and efficacy, we evaluated this vaccine candidate in mice with two different adjuvants and a heterologous boost with a recombinant modified vaccinia Ankara virus (MVA) expressing the antigen 85A (MVA85A). We observed that boosting with MVA85A did not improve total IgG or specific isotypes in serum induced by one or two doses of 6611 formulated with incomplete Freund's adjuvant (IFA). However, when 6611 was formulated with ISA201 adjuvant, MVA85A boost enhanced the production of IFNγ, Th1/Th17 cytokines (IL-2, TNF, IL-17A) and IL-6, IL-4 and IL-10. Also, this group showed the highest levels of IgG2b and IgG3 isotypes, both important for better protection against Map infection in the murine model. Finally, the heterologous scheme elicited the highest levels of protection after Map challenge (lowest CFU count and liver lesion score). In conclusion, our results encourage further evaluation of 6611 strain + ISA201 prime and MVA85A boost in bovines.

01 Feb 2024·Veterinary Microbiology

Construction and immunogenicity of Senecavirus A virus-like particle vaccine with adjuvant

Article

Author: Xie, Yubiao ; Li, Zhuoxin ; Jin, Ningyi ; Zhang, He ; Han, Jicheng ; Wang, Peng ; Lu, Huijun ; Zhang, Jinyong

Senecavirus A (SVA) is constantly associated with vesicular disease in pigs, and the clinical symptoms of pig infection with SVA are indistinguishable from other porcine vesicular diseases. Vaccine is one of the best methods to eliminate and control the spread of SVA. Virus-like particles (VLPs) can play important roles in prevention for infectious diseases. Here, the SVA VLPs was assembled by the baculovirus expression vector system, and the immunogenicity of the SVA VLPs mixed with different adjuvants were evaluated in mice and pigs. Two recombinant baculoviruses (rPFBD-VP1-VP3 and rPFBD-VP2-VP4) were constructed, which co-infected with Sf9 suspension cells to assemble SVA VLPs successfully. SVA VLPs mixed with ISA201 adjuvant and ISA201 +Poly(I:C) adjuvant produced higher levels of neutralizing antibody, specific antibody (total IgG, IgG1, IgG2a and IgG2b) and cytokines in the T cells. And there was no significant difference between SVA VLPs+ 201 group and SVA VLPs+Poly(I:C)+ 201 group. Pigs immunized with high dose of SVA VLPs mixed with ISA201 adjuvant could produce higher titers of neutralizing antibody and SVA-specific antibody. Furthermore, the protection rates of SVA VLPs-H and SVA VLPs-L were 100% and 80%, and the viral load of SVA VLPs-H group is the lowest in all SVA VLPs groups. It is the first time to develop the SVA VLPs using the baculovirus expression vector system, which may lay the foundation for the research and development of SVA vaccine.

100 Deals associated with ISA-201

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Head and Neck Neoplasms	Phase 2	-	ISA Pharmaceuticals BV	-
Human Papillomavirus Infection	Phase 2	-	ISA Pharmaceuticals BV	-
Human Papillomavirus-16 Positive	Phase 1	NL	ISA Pharmaceuticals BV	01 Mar 2015
Precancerous Conditions	Discovery	NL	ISA Pharmaceuticals BV	01 Mar 2015
Visible Lesion	Discovery	NL	ISA Pharmaceuticals BV	01 Mar 2015